Clinical Trials
116 trialsLutécio
Instituto do Cancer do Estado de São Paulo
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
University of Southern California
Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer
Centre Antoine Lacassagne
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
Weill Medical College of Cornell University
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
M.D. Anderson Cancer Center
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer
Dana-Farber Cancer Institute
MEDINDUCTION
Gustave Roussy, Cancer Campus, Grand Paris
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
University of California, Irvine
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer
M.D. Anderson Cancer Center
Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities
Wake Forest University Health Sciences
A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer
University of Iowa
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Tufts Medical Center
I-FLOAT
University of Chicago
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Emory University
Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
Thomas Jefferson University
RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
M.D. Anderson Cancer Center
Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers
Ohio State University Comprehensive Cancer Center
Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
University of California, San Diego
Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis
Johns Hopkins University
Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery
M.D. Anderson Cancer Center
DOP
The Netherlands Cancer Institute
Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
CCODG-NSCLC
Shanghai Jiao Tong University School of Medicine
Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.
University of Texas Southwestern Medical Center
Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
Medical University of South Carolina
Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer
University of Nebraska
Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors
Roswell Park Cancer Institute
EDALINE
Spanish Breast Cancer Research Group
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer
University of California, Davis
PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic
Roswell Park Cancer Institute
Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer
Zhejiang Provincial People's Hospital
Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer
Weill Medical College of Cornell University
Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Safety of the Combination of SH003 and Docetaxel in Patients With Solid Cancer
Kyunghee University Medical Center
Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer
Asan Medical Center
Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck
University of Cincinnati
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
University of Wisconsin, Madison
Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
Milton S. Hershey Medical Center
LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel
Hackensack Meridian Health
WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck
University of Washington
Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy
University of Massachusetts, Worcester
Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
M.D. Anderson Cancer Center
A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer
University of Iowa
Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
Montefiore Medical Center